INVESTIGATIVE REPORT

Shiny White Streaks: A Sign of Malignancy at Dermoscopy of Pigmented Skin Lesions

Danielle SHITARA¹,², Priscila ISHIOKA¹,², Yarel ALONSO-PINEDO¹,², Leyla PALACIOS-BEJARANO¹,³, Cristina CARRERA¹,⁴, Josep MALVEHY¹,⁴ and Susana PUIG¹,⁴

¹Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain, ²Department of Dermatology, Federal University of São Paulo, São Paulo, Brazil, ³Instituto Dermatologico de Jalisco “Dr Jose Barba Rubio”, Guadalajara, Jalisco, Mexico, and ⁴CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain

The aim of this study was to evaluate the practical importance of the presence of shiny white streaks (SWS) (chrysalis or crystalline structures in polarized dermoscopy) for suspicion of malignancy, diagnosis of melanoma, and pre-operative estimation of Breslow thickness and its correlation with total dermoscopy score (TDS). SWS were present in 13.6% of 800 consecutive excised lesions. The presence of SWS was associated with malignancy (odds ratio (OR) 10.534, 95% confidence interval (95% CI) 6.357–17.455, p < 0.0005), in the context of melanocytic lesions with invasive melanoma (OR 10.333, 95% CI 3.812–28.014) and melanomas with high TDS (OR 6.286, 95% CI 1.673–23.619), but was also a factor in the diagnosis of featureless and some thin melanomas. These results corroborate the clinical applicability of SWS in aiding the diagnosis of malignancy and helping to raise the general dermatologist’s awareness in cases of doubt and featureless lesions. Key words: dermoscopy; shiny white streaks; polarized light; chrysalis; melanoma; basal cell carcinoma.

Accepted Apr 29, 2013; Epub ahead of print Sep 3, 2013


Susana Puig, Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Villarroel 170, ES-08036 Barcelona, Spain. E-mail: susipuig@gmail.com, spuig@clinic.ub.es

Dermoscopy has proven valuable in aiding the diagnosis of melanoma compared with naked-eye examination (1–3). In fact, not only can dermoscopy yield a 10–27% higher sensitivity than clinical diagnosis of melanoma, the use of the dermatoscope also improves recognition of its simulators, such as benign tumours (e.g. seborrheic keratosis (4)) or malignant tumours (e.g. pigmented basal cell carcinomas (BCC)) (4).

Previous studies have shown a good correlation between selected dermoscopy criteria and the histopathology of melanoma for the pre-operative evaluation of tumour depth (5, 6). In these studies, the presence of some dermoscopic features such as pigment network and radial streaming were associated with radial growth, whereas grey-blue areas and dotted vessels were related to the vertical growth phase. Furthermore, the dermoscopy ABCD rule was tested as a predictor of melanoma thickness, with increasing total dermoscopy score (TDS) values being related to increasing thickness of the lesions (7).

Among the dermoscopic algorithms described in the literature (8–14), the ABCD rule is a simple, easily learned, simplified semi-quantitative approach that calculates the TDS for the diagnosis of melanoma, with reported sensitivity varying from 84.4% to 97.9% and specificity from 74.5% to 90.3% (10, 13). It is of note that, in spite of the increment in sensitivity in melanoma diagnosis, there is still a chance of misdiagnosing melanoma (false-negative cases (15)), depending on dermoscopic expertise (3, 16, 17). Even so, despite the experience of the dermoscopists, melanomas diagnosed in follow-up programmes of high-risk patients were misclassified by TDS (50% of cases) and the majority did not present a multi-component or unspecific pattern, as observed in a recent study (18). The authors suggested that early-diagnosed melanomas might not yet present characteristic features of melanoma, thus imposing difficulties in their early recognition.

With the recent use of polarized dermatoscopes (PD), some differences compared with contact non-polarized dermoscopy (NPD) in the dermoscopy image have been pointed out regarding: colour (melanin appears darker), visualization of structures (improvement in visualization of vessels, but not of peppering or regression, nor of superficial structures such as milia-like cysts and comedo-like openings), as well as recognition of structures not seen under NPD. PD appears to block the superficially reflected light more efficiently than non-polarized dermoscopes, accounting for these differences in image and depth of structure visualization: NPD allows better visualization of superficial structures, whilst PD allows better appreciation of deeper structures, such as collagen and vessels (19, 20).

Shiny white streaks (SWS) (also named chrysalis or, as recently proposed, crystalline structures) were described as shiny, bright, often orthogonal, linear streaks, seen only under PD, in dermatofibromas, scars, melanomas, BCCs (21–24) and, more recently,
melanocytic naevi, mainly Spitz naevi (25). Recently, a classification of SWS types has been proposed according to different diagnoses (26). Differing from negative pigment network, which was described by Menzies and revised recently by Bassoli et al. (27) as relatively light areas making up the “cords” of the network, and darker areas filling the holes; SWS are often linear unconnected white lines that do not make up a network pattern (28). SWS were related to angular dependence of polarized light and collagen orientation in the underlying stroma of tumours with an increased amount of dermal collagen, but its definite histopathological counterpart is unknown (21, 25, 26, 29).

It has been suggested that SWS may be of importance in the diagnosis of melanoma, as a clue to their differentiation from naevi, and in the identification of more advanced lesions (26). In a recent study SWS were observed more commonly in invasive melanomas compared with in situ melanomas, and melanomas with SWS were thicker than those without SWS, suggesting that the presence of this dermoscopic parameter may be related to a higher chance of dermal invasion and thicker tumours (26).

The aim of this study was to evaluate the importance of the presence of SWS in the suspicion of malignancy, in the diagnosis of melanoma and in the prognostic evaluation regarding depth of invasion (Breslow) in melanoma.

MATERIALS AND METHODS

All lesions excised from January 2010 to August 2011 in the Melanoma Unit of Hospital Clinic, Barcelona, with dermoscopy images were included in this retrospective study.

Dermoscopy images were retrospectively evaluated using images obtained with a DermLite Foto (3GEN, LLC, Dana Point, CA), and a Canon PowerShot G7 (Canon Inc, Japan).

Only lesions with a histopathological diagnosis were included in the study. Lesions were primarily analysed for the presence or absence of SWS. In the case of surgical scarring due to a previous partial biopsy (e.g. lentigo maligna melanoma (LMM) on the face), the evaluation of the SWS did not include this part of the tumour. The lesions were then matched to the histopathological diagnosis. In cases of melanoma, the following clinical and histopathological parameters were also obtained: lesion site, Breslow thickness and histopathological subtypes of BCC (nodular BCC (nBCC), superficial BCC (sBCC), trichilemmal BCC (tBCC), infiltrative BCC (iBCC)) were recorded.

Statistical analysis

Pearson’s χ² test was used to evaluate the association between categorical variables. If the expected frequency was < 5, Fisher’s exact test was used (Table I). The 95% CIs were obtained by the exact binomial method, and the overall risk (OR) calculated. Means and median were calculated. Student’s t-test was used to compare the mean of quantitative variables.

RESULTS

A total of 800 dermoscopic images were analysed for the presence or absence of SWS. The data-set is shown in Table I, including benign and malignant, melanocytic and non-melanocytic tumours (Figs 1–6).

Of the melanoma set (n = 125), 56 were in situ (44.8%), 69 invasive (55.2%; mean Breslow thickness 1.7 mm), 27 were thin melanomas (48.2%; < 1 mm;) and 29 were thick (51.8%; ≥ 1 mm). There were 13 melanomas with no Breslow thickness noted in the histopathological record (4 recurrent melanomas, 5 metastasis, 4 not evaluable). As regards histopathological subtype, 69 were SSM (55.2%), 46 LMM (36.8%), 5 melanoma metastasis (4%), 3 NM (2.4%) and 2 SM (1.6%). Regarding the lesion site, 47 melanomas were located on the head, 38 on the trunk, and 40 on the limbs. Scarring from a previous biopsy was observed in 18 melanomas (5 SSM and 13 LMM). The majority of melanomas had a TDS score higher than or equal to the threshold for malignancy (5.45; 67.6%), with mean TDS: 5.97. Nevertheless, 25 melanomas scored less than 5.44 (32.4%), including 17 that scored in the malignancy range (< 4.75; 22.7%) (Table I).

SWS was present in 41 melanomas (6/56 in situ, 31/56 with measurable Breslow thickness and 4/13 other lesions), i.e. metastasis, recurrent melanoma, melanomas without measurable Breslow thickness (Figs 1, 3 and 4), these being 24 SSM (58.5%), 11 (26.8%) LMM, 3 NM (7.4%), 2 SM (4.9%) and 1 metastasis (2.4%), while only 1.6% of all excised melanocytic naevi presented SWS (Table I).

The presence of SWS was associated with a 10-fold increased risk of malignancy (melanomas, BCCs, SCCs, neuroendocrine carcinoma) (see Table I).
The presence of shiny white streaks (SWS) correlated with a 10.33-fold increased risk of a diagnosis of invasive melanomas compared with in situ melanomas (OR 10.33, 95% CI 3.812–28.014, \( p < 0.005 \)). In invasive melanoma, the mean Breslow value for melanomas with SWS was 2.28 mm, significantly higher than in melanomas without SWS. Only 6 out of 56 (10.7%) in situ melanomas presented SWS, while 35 of 69 of the invasive melanomas (50.7%) had SWS. The presence of SWS correlated with a 10.33-fold increased risk of a diagnosis of invasive melanomas compared with in situ melanomas (OR 10.33, 95% CI 3.812–28.014, \( p < 0.005 \)). In invasive melanoma, the mean Breslow value for melanomas with SWS was 2.28 mm, significantly higher than in melanomas without SWS.

### Table I. Presence of shiny white streaks (SWS) according to diagnosis, total dermoscopy score (TDS) in melanomas and Breslow thickness in invasive melanomas

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Cases</th>
<th>SWS</th>
<th>Yes</th>
<th>No</th>
<th>( p )-value</th>
<th>Odds ratio</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma in situ</td>
<td>56</td>
<td>6</td>
<td>50</td>
<td></td>
<td>(&lt; 0.0005)</td>
<td>10.333</td>
<td>3.812–28.014</td>
</tr>
<tr>
<td>Invasive melanoma( ^a )</td>
<td>56</td>
<td>31</td>
<td>25</td>
<td>10</td>
<td>(&lt; 0.0005)</td>
<td>4.463</td>
<td>1.444–13.792</td>
</tr>
<tr>
<td>Breslow thickness ( &lt; 1 ) mm( ^a )</td>
<td>27</td>
<td>10</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breslow thickness ( \geq 1 ) mm( ^a )</td>
<td>29</td>
<td>21</td>
<td>8</td>
<td></td>
<td>(&lt; 0.009)</td>
<td>4.463</td>
<td>1.444–13.792</td>
</tr>
<tr>
<td>Others( ^a )</td>
<td>13</td>
<td>4</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TDS ( &lt; 5.45 )</td>
<td>25</td>
<td>3</td>
<td>22</td>
<td></td>
<td>(&lt; 0.0005)</td>
<td>6.286</td>
<td>1.673–23.619</td>
</tr>
<tr>
<td>TDS ( \geq 5.45 )</td>
<td>52</td>
<td>24</td>
<td>28</td>
<td></td>
<td>(&lt; 0.006)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total melanoma</td>
<td>125</td>
<td>41</td>
<td>84</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other malignant tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal cell carcinoma (BCC)</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infiltrative BCC</td>
<td>20</td>
<td>6</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodular BCC</td>
<td>35</td>
<td>12</td>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( p )BCC</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superficial BCC</td>
<td>65</td>
<td>19</td>
<td>46</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trichilemmal BCC</td>
<td>9</td>
<td>2</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total BCC</td>
<td>133</td>
<td>41</td>
<td>92</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>21</td>
<td>3</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merkel</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total malignant</td>
<td>280</td>
<td>86</td>
<td>194</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naevus</td>
<td>305</td>
<td>5</td>
<td>300</td>
<td>(&lt; 0.0005)</td>
<td>10.534</td>
<td>6.357–17.455</td>
<td></td>
</tr>
<tr>
<td>Seborrhoeic keratosis</td>
<td>49</td>
<td>2</td>
<td>47</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatofibroma</td>
<td>11</td>
<td>6</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other benign lesions</td>
<td>91</td>
<td>0</td>
<td>91</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actinic keratosis</td>
<td>36</td>
<td>4</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lichen planus like keratosis</td>
<td>9</td>
<td>2</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solar lentigos</td>
<td>19</td>
<td>2</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total benign</td>
<td>520</td>
<td>21</td>
<td>499</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\( ^a \)Only invasive melanomas with measurable Breslow were included.

\( ^a \)Includes lesions without measured Breslow thickness (i.e. metastasis, relapses). These lesions were not included in the in situ/invasive evaluation).

\( ^a \)Only melanomas not located in face or acral sites were included.

\( ^a \)Lesions described in \( ^a \) were also not included in the evaluation of thin/thick melanomas.

\( ^a \)comparing total malignant with total benign.
nomas without SWS (0.9 mm) \((p < 0.005)\). Melanomas with SWS had a 4.46-fold increased risk of being thick melanomas (see Table 1).

Of all LMM with SWS, 4 were in situ, 5 invasive and 2 had no Breslow value available. Interestingly, invasive LMM with SWS were thicker than SSM with SWS, the mean and median Breslow values for LMM with SWS were 4.62 mm and 3.6 mm, respectively, and for SSM with SWS 1.43 mm and 1.03 mm.

SWS statistical findings regarding the dermoscopic parameters evaluated for melanoma are summarized in Table SI1.

The mean TDS score for melanomas with SWS was 6.61 and without SWS 5.62 \((p < 0.05)\). When controlled for TDS, SWS were more frequent in TDS scores higher than 5.45 \((p < 0.05)\) (Fig. 3). Notwithstanding the small number of cases, SWS were also observed in 3 cases with TDS < 4.75 (3.8%), 1 of which was a Spitzoid melanoma (Fig. 1).

The BCC data-set is detailed in Table SI1. Of all the BCCs, 30.8% presented SWS (Fig. 2) and there was no statistically significant difference regarding histopathological subtype. Interestingly, SWS were also observed more frequently in BCCs with ulceration \((p < 0.005)\) (Fig. 2). None of the other criteria evaluated presented a statistically significant difference.

As previously described, SWS were only visible when polarized light was used and

Fig. 3. (A) Clinical picture, and (B–D) dermoscopy images with polarized light at different angles (B 0°, C 45° and D 90°). Change in the polarization angle changes the number, location and morphology of shiny white streaks (SWS). Dermoscopy total dermoscopy score (TDS) of 7.9 (asymmetry in 2 axes: 2.6; all abrupt borders = 0.8; 5 colours: brown, black, blue-grey, white and red = 2.5; 4 dermoscopic features; homogeneous areas, pigment network, dots and globules = 2).

Fig. 4. Change in polarization angle influences the observation of shiny white streaks (SWS). (A) Dermoscopy with polarized light of a melanoma at a polarization angle that enhances the presence of SWS. (B) Dermoscopy with polarized light of the same melanoma at a 90° polarization angle as (A). SWS are less evident, while regression (peppering) is more visible.

Fig. 5. Clinical picture (upper right) and dermoscopy (main image) with polarized light of a Merkel carcinoma (neuroendocrine tumour) showing shiny white streaks (SWS). SWS (some of them indicated with an arrow) were associated with the presence of ulceration and thick arborizing vessels.

Fig. 6. Clinical picture (upper right) and dermoscopy (main image) with polarized light of a blue naevus showing shiny white streaks (SWS). The deep stromal component of this blue naevus may be the cause of the presence of SWS.

---

1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1683
DISCUSSION

As an example of structures seen only under PD, SWS was described in a variety of lesions including melanomas, BCCs, dermatofibromas, biopsy scars and melanocytic naevi (22–25). SWS has been suggested to represent dermal fibroplasia seen in benign lesions such as dermatofibromas and scars, and in malignant lesions, due to tumour-induced stromal reaction and extracellular matrix changes (21).

It has been suggested in previous studies (Table SII1) (22, 25, 26) that SWS may be of importance in the diagnosis of melanoma, as a clue to their differentiation from nevi. In fact, we observed SWS in 32.8% of melanomas, while only 1.6% of all excised melanocytic naevi presented SWS, thus corroborating the results from previous studies. Table SII1 compares the results of 4 different studies.

Apart from its usefulness in melanoma diagnosis, the presence of SWS implied a 10-fold increased risk of malignancy (melanomas, BCC, SCC, neuroendocrine carcinoma) (OR: 10.534, 95% CI 6.357–17.455, p<0.0005) (Fig. 5). Thus, with the exception of dermatofibromas in which SWS were frequently observed, the presence of this dermoscopic parameter is a strong clue to malignancy.

Recently, Balagula et al. (25) described the presence of SWS in 1.8% of lesions, melanocytic as well as non-melanocytic, in contrast with the 13.4% in our study. This difference is probably due to differences in the data-set of each study: only 264 lesions in the former study were suspicious of malignancy and were biopsied, whilst only lesions with histopathological diagnosis were included in our study (800 lesions) (Table SII1). We observed SWS in 32.8% of melanomas, similar to the 31% observed by Di Stefani et al. (22) (Table SII1). The percentage of BCCs with SWS in our sample (30.8%) was smaller than in previous reports (47.6% and 42.4%) (25, 26). It is notable that SWS did not correlate with any histopathological subtype of BCC. In a recent study by Liebman et al. (26) the presence of SWS of any length in invasive melanomas compared with in situ melanomas, and those with SWS were also thicker than those without. In our study, the presence of SWS correlated with a 10.33-fold increased risk of a diagnosis of invasive melanoma compared with in situ melanomas (OR 10.33, 95% CI 3.812–28.014, p<0.005), greater than the value obtained by Balagula et al. (25) (OR 3.4, 95% CI 1.9–6.3). Also, the presence of SWS gave a 4.46-fold increased risk of thick melanomas compared with thin (OR=4.46, 95% CI 1.444–13.792, p=0.009). This data suggests that SWS may be related to an increased probability of invasive melanoma and thicker tumours. Nevertheless, the presence of SWS could also be helpful in the diagnosis of thin melanomas, especially those with few diagnostic criteria. In our study melanoma set, 10 out of 27 thin melanomas and 6 out of 56 in situ melanoma presented SWS.

As regards the clinical evaluation of melanoma thickness pre-operatively, the presence of SWS resulted in a sensitivity of 67.7% and specificity of 68% for thick melanoma (>1 mm thickness), which is in agreement with previous studies (6, 30).

Nachbar et al. (8) described a simplified semi-quantitative approach to the diagnosis of melanoma, the ABCD rule (TDS score). The threshold for malignancy was stipulated as 5.45, with values between 5.44 and 4.75 being suspicious lesions and those below 4.75 being benign. This yields a sensitivity of 84.4–97.9% and a specificity of 74.5–90.3% in the literature. The present study was the first, to our knowledge, to correlate the TDS score with the presence of SWS. SWS were more frequent in melanomas with a TDS score suggestive of malignancy (>5.45). Nonetheless, SWS were also observed in 3 cases with TDS in the benignancy range (<4.75; 3.8%), highlighting the possible importance of SWS in the diagnostic aid of featureless melanomas, such as the case of Spitzoid melanoma (Fig. 1).

Melanomas with the following dermoscopic diagnostic criteria had a greater possibility of displaying SWS: presence of structureless areas, irregular blotch; also multi-component or unspecific pattern (Table SI1).

In contrast to previous data in the literature, our study obtained a significant association between SWS and regression, such that melanomas with regression were 3.2 times more likely to display SWS than those without (Table SII1). This fact could be related to the previously suggested histopathological correlation to SWS, dermal fibroplasia, since regression may be related to further stromal reaction and thus justify the increased detection of SWS in melanomas with regression. Also, the presence of SWS in our study was associated with other dermoscopy criteria that are associated with dermal invasion, such as blue-white veil, milky-red globules or polymorphous vessels in melanoma, or white patch in dermatofibromas, or deep blue colour in blue naevus (Fig. 6), reinforcing the hypothesis that the optical artefact responsible for to SWS is located in the dermis (Fig. 5). We have observed that the change in the angle of polarization may enhance observation of either SWS or regression structures such as peppering. We speculate that the reflection of light related to dermal fibroplasia, which on the one hand favours SWS observation, may on the other hand interfere with the visualization of other structures such as peppering (Fig. 4).
ACKNOWLEDGEMENTS

We are indebted to all our patients and their families; to our colleagues and to our nurses, Pablo Iglesias, Daniel Gabriel and M. Eugenia Moliner. We also thank Helena Kruyer for her help with text editing.

Funding/support. The research at the Melanoma Unit in Barcelona is partially funded by Grants from Fondo de Investigaciones Sanitarias P.I. 09/01393 and P.I. 12/00840, Spain; by the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain; by the AGAUR 2009 SGR 1337 of the Catalan Government, Spain; by the European Commission under the 6th Framework Programme, Contract nr: LSHC-CT-2006-018702 (GenoMEL).

Role of the sponsors

The authors declare no conflicts of interest.

REFERENCES